Related Experiment Videos

Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with

Petra Tesarová1, Marta Kalousová, Marie Jáchymová

  • 1Department of Oncology, 1st School of Medicine, Charles University and General University Hospital, Prague, Czech Republic. tesarova.petra@seznam.cz

Cancer Investigation
|December 7, 2007
PubMed

Insights

Soluble receptor for advanced glycation end products (sRAGE) levels are lower in breast cancer patients, potentially driving disease progression. Higher sRAGE levels correlate with better outcomes and specific genetic variations in RAGE.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The receptor for advanced glycation end products (RAGE) pathway is implicated in cancer progression and metastasis.
  • Soluble RAGE (sRAGE) acts as a physiological inhibitor of RAGE-mediated effects, suggesting higher sRAGE levels may indicate a better prognosis.

Purpose of the Study:

  • To investigate the association between serum sRAGE levels, RAGE gene polymorphisms, and clinical parameters in breast cancer patients.
  • To determine if sRAGE levels correlate with breast cancer stage, grade, and receptor status.

Main Methods:

  • Serum sRAGE concentrations and RAGE gene polymorphisms (Gly82Ser, 2184 AG) were analyzed in 120 breast cancer patients and 92 healthy controls.
  • Patients were sub-classified based on clinical stage, histologic grade, and expression of estrogen receptors, progesterone receptors, and Her2/neu.

Main Results:

  • Breast cancer patients exhibited lower serum sRAGE levels compared to healthy controls, despite higher AGEs concentrations.
  • Elevated sRAGE levels were observed in patients with advanced stage (III) disease, low histologic grade, positive estrogen receptors, and intermediate Her2/neu positivity.
  • RAGE gene polymorphisms significantly influenced sRAGE levels.

Conclusions:

  • Decreased serum sRAGE levels in breast cancer patients may contribute to disease progression.
  • Higher sRAGE levels are associated with favorable prognostic factors (low grade, ER-positive) and may represent a compensatory mechanism against cancer progression.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...